Cynomolgus studies with lead TRACTrs have demonstrated safety proof-of-concept to support IND-enabling development activities. Janux-led TRACTr development candidate selection is ongoing with multiple programs entering IND-enabling studies in 2021 to provide a broad portfolio of tumor-specific immune-activating therapeutics. In addition, Janux is developing a costimulatory bispecific that has demonstrated activity both as a single-agent and in combination with TRACTrs.

Lead DiscoveryLead OptimizationIND EnablingPhase 1
TROP2-TRACTr

PSMA-TRACTr

EGFR-TRACTr

HER2-TRACTr

Costim bispecific

DrugStage
TROP2-TRACTr
IND Enabling
PSMA-TRACTr
IND Enabling
EGFR-TRACTr
IND Enabling
HER2-TRACTr
Lead Optimization
Costim bispecific
Lead Optimization